Company intelligence / Profile preview

iRhythm Technologies

San Francisco, California, United Statesirhythmtech.com ↗

Ownership: Public · IRTC
Employees: ~2000
Development stage: Commercial

Overview

iRhythm’s Zio platform has been used in over 8 million patients with more than 1.5 billion hours of heartbeat data analyzed. The FDA-cleared deep-learned AI algorithm powering the service has demonstrated accuracy comparable to expert cardiologists. The company’s products are commercially available in the US and have shown high patient compliance rates (~99%) and strong physician agreement on diagnostic reports

Therapeutic areas: PulmonologyCardiovascularNeurology
Modalities: Device
Industry: Physiological Monitoring

Drug pipeline

2 assets

Zio XT

Commercial

Indications: Cardiac arrhythmia, Atrial fibrillation

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $3.9B
Total revenue: $224.2M
Enterprise value: $4.1B

Beyond the preview

Go deeper on iRhythm Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iRhythm Technologies.

Explore the full profile